• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

基于更新后的ESGO/ESTRO/ESP指南看子宫内膜癌的新病理及临床见解

New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines.

作者信息

Santoro Angela, Angelico Giuseppe, Travaglino Antonio, Inzani Frediano, Arciuolo Damiano, Valente Michele, D'Alessandris Nicoletta, Scaglione Giulia, Fiorentino Vincenzo, Raffone Antonio, Zannoni Gian Franco

机构信息

Unità di Ginecopatologia e Patologia Mammaria, Dipartimento Scienze della Salute della Donna, del Bambino e di Sanità Pubblica, Fondazione Policlinico Universitario A. Gemelli IRCCS, Largo A. Gemelli 8, 00168 Roma, Italy.

Gynecology and Obstetrics Unit, Department of Neuroscience, Reproductive Sciences and Dentistry, School of Medicine, University of Naples Federico II, 80131 Naples, Italy.

出版信息

Cancers (Basel). 2021 May 26;13(11):2623. doi: 10.3390/cancers13112623.

DOI:10.3390/cancers13112623
PMID:34073635
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC8198052/
Abstract

Endometrial carcinoma represents the most common gynecological cancer in Europe and the USA. Histopathological classification based on tumor morphology and tumor grade has played a crucial role in the management of endometrial carcinoma, allowing a prognostic stratification into distinct risk categories, and guiding surgical and adjuvant therapy. In 2013, The Cancer Genome Atlas (TCGA) Research Network reported a large scale molecular analysis of 373 endometrial carcinomas which demonstrated four categories with distinct clinical, pathologic, and molecular features: POLE/ultramutated (7% of cases) microsatellite instability (MSI)/hypermutated (28%), copy-number low/endometrioid (39%), and copy-number high/serous-like (26%). In the present article, we report a detailed histological and molecular review of all endometrial carcinoma histotypes in light of the current ESGO/ESTRO/ESP guidelines. In particular, we focus on the distribution and prognostic value of the TCGA groups in each histotype.

摘要

子宫内膜癌是欧洲和美国最常见的妇科癌症。基于肿瘤形态和肿瘤分级的组织病理学分类在子宫内膜癌的管理中发挥了关键作用,可将预后分层为不同的风险类别,并指导手术和辅助治疗。2013年,癌症基因组图谱(TCGA)研究网络报告了对373例子宫内膜癌的大规模分子分析,结果显示出具有不同临床、病理和分子特征的四类:POLE/超突变型(7%的病例)、微卫星不稳定(MSI)/高突变型(28%)、拷贝数低/子宫内膜样型(39%)和拷贝数高/浆液性样型(26%)。在本文中,我们根据当前的ESGO/ESTRO/ESP指南,报告了对所有子宫内膜癌组织学类型的详细组织学和分子学综述。特别是,我们重点关注TCGA各分组在每种组织学类型中的分布及预后价值。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e3d/8198052/65c9c98d81a8/cancers-13-02623-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e3d/8198052/51b6f4115a23/cancers-13-02623-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e3d/8198052/65c9c98d81a8/cancers-13-02623-g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e3d/8198052/51b6f4115a23/cancers-13-02623-g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/9e3d/8198052/65c9c98d81a8/cancers-13-02623-g002.jpg

相似文献

1
New Pathological and Clinical Insights in Endometrial Cancer in View of the Updated ESGO/ESTRO/ESP Guidelines.基于更新后的ESGO/ESTRO/ESP指南看子宫内膜癌的新病理及临床见解
Cancers (Basel). 2021 May 26;13(11):2623. doi: 10.3390/cancers13112623.
2
Impact of endometrial carcinoma histotype on the prognostic value of the TCGA molecular subgroups.子宫内膜癌组织学类型对 TCGA 分子亚群预后价值的影响。
Arch Gynecol Obstet. 2020 Jun;301(6):1355-1363. doi: 10.1007/s00404-020-05542-1. Epub 2020 Apr 15.
3
Endometrial carcinoma: 10 years of TCGA (the cancer genome atlas): A critical reappraisal with comments on FIGO 2023 staging.子宫内膜癌:TCGA(癌症基因组图谱)10 年:批判性再评价及对 2023 年 FIGO 分期的评论。
Gynecol Oncol. 2024 Jul;186:94-103. doi: 10.1016/j.ygyno.2024.04.008. Epub 2024 Apr 13.
4
High-grade endometrial carcinomas: Morphologic spectrum and molecular classification.高级别子宫内膜癌:形态学谱与分子分类
Semin Diagn Pathol. 2022 May;39(3):176-186. doi: 10.1053/j.semdp.2021.11.002. Epub 2021 Nov 20.
5
TCGA Molecular Prognostic Groups of Endometrial Carcinoma: Current Knowledge and Future Perspectives.TCGA 子宫内膜癌分子预后分组:当前认识与未来展望。
Int J Mol Sci. 2022 Oct 2;23(19):11684. doi: 10.3390/ijms231911684.
6
Molecular Genetics of Endometrial Carcinoma.子宫内膜癌的分子遗传学。
Annu Rev Pathol. 2019 Jan 24;14:339-367. doi: 10.1146/annurev-pathol-020117-043609. Epub 2018 Oct 17.
7
Colombian consensus for the molecular diagnosis of endometrial cancer.哥伦比亚子宫内膜癌分子诊断共识。
Rev Colomb Obstet Ginecol. 2024 Jun 17;75(1):4060. doi: 10.18597/rcog.4060.
8
FIGO staging of endometrial cancer: 2023.国际妇产科联盟(FIGO)子宫内膜癌分期:2023 年。
J Gynecol Oncol. 2023 Sep;34(5):e85. doi: 10.3802/jgo.2023.34.e85. Epub 2023 Aug 8.
9
Classification of Endometrial Carcinoma: New Perspectives Beyond Morphology.子宫内膜癌的分类:超越形态学的新视角。
Adv Anat Pathol. 2019 Nov;26(6):421-427. doi: 10.1097/PAP.0000000000000251.
10
Identification of mutated group using a molecular and immunohistochemical classification of endometrial carcinoma to improve prognostic evaluation for adjuvant treatments.采用分子和免疫组织化学分类的方法鉴定突变组,以改善子宫内膜癌辅助治疗的预后评估。
Int J Gynecol Cancer. 2020 May;30(5):640-647. doi: 10.1136/ijgc-2019-000871. Epub 2020 Mar 12.

引用本文的文献

1
Beyond the Microscope: Integrating Liquid Biopsies into the Molecular Pathology Era of Endometrial Cancer.超越显微镜:将液体活检纳入子宫内膜癌分子病理学时代
Int J Mol Sci. 2025 Aug 19;26(16):7987. doi: 10.3390/ijms26167987.
2
Predictive Biomarkers for Immunotherapy in Endometrial Carcinoma.子宫内膜癌免疫治疗的预测生物标志物
Cancers (Basel). 2025 Jul 22;17(15):2420. doi: 10.3390/cancers17152420.
3
A Case Report to Reflect on the Origins of MMRd Mesonephric-like Ovarian Adenocarcinoma: Can It Be Defined as a Mϋllerian Neoplasm?

本文引用的文献

1
HER2 Expression in Endometrial Cancers Diagnosed as Clear Cell Carcinoma.诊断为透明细胞癌的子宫内膜癌中 HER2 的表达。
Int J Gynecol Pathol. 2022 Mar 1;41(2):132-141. doi: 10.1097/PGP.0000000000000783.
2
Mesonephric and mesonephric-like carcinomas of the female genital tract: molecular characterization including cases with mixed histology and matched metastases.女性生殖道中肾和中肾样癌:分子特征分析,包括具有混合组织学和配对转移的病例。
Mod Pathol. 2021 Aug;34(8):1570-1587. doi: 10.1038/s41379-021-00799-6. Epub 2021 Mar 26.
3
Clinical features of ProMisE groups identify different phenotypes of patients with endometrial cancer.
一份关于反思错配修复缺陷(MMRd)中肾样卵巢腺癌起源的病例报告:它能被定义为苗勒管肿瘤吗?
Int J Mol Sci. 2025 May 29;26(11):5245. doi: 10.3390/ijms26115245.
4
Integrative analysis of DNA methylation, RNA sequencing, and genomic variants in the cancer genome atlas (TCGA) to predict endometrial cancer recurrence.癌症基因组图谱(TCGA)中DNA甲基化、RNA测序和基因组变异的综合分析以预测子宫内膜癌复发
Front Genet. 2025 Apr 28;16:1569122. doi: 10.3389/fgene.2025.1569122. eCollection 2025.
5
Differential Localization of β-Catenin Protein in CTNNB1 Mutant Endometrial Cancers Results in Distinct Transcriptional Profiles.β-连环蛋白在CTNNB1突变型子宫内膜癌中的差异定位导致不同的转录谱。
Mod Pathol. 2025 May 8;38(9):100791. doi: 10.1016/j.modpat.2025.100791.
6
Identification of prognostic biomarkers for endometrioid endometrial carcinoma based on the miRNA and mRNA co-expression network regulated by estradiol.基于雌二醇调节的miRNA与mRNA共表达网络鉴定子宫内膜样腺癌的预后生物标志物
Clinics (Sao Paulo). 2025 May 3;80:100672. doi: 10.1016/j.clinsp.2025.100672. eCollection 2025.
7
The Value of Integrating Hormone Receptors into Immunohistochemistry-Based Simplified Molecular Classification in Endometrial Cancer.将激素受体纳入子宫内膜癌基于免疫组织化学的简化分子分类中的价值
Cancer Manag Res. 2025 Apr 24;17:869-880. doi: 10.2147/CMAR.S514680. eCollection 2025.
8
Association of peripheral monocytic myeloid-derived suppressor cells with molecular subtypes in single-center endometrial cancer patients receiving carboplatin + paclitaxel/avelumab (MITO-END3 trial).外周血单核细胞来源的髓系抑制细胞与接受卡铂+紫杉醇/阿维鲁单抗治疗的单中心子宫内膜癌患者分子亚型的相关性(MITO-END3试验)
Cancer Immunol Immunother. 2025 Apr 17;74(6):172. doi: 10.1007/s00262-025-04021-3.
9
Comprehensive Review of Endometrial Cancer: New Molecular and FIGO Classification and Recent Treatment Changes.子宫内膜癌综合综述:新的分子和国际妇产科联盟(FIGO)分类以及近期治疗变化
J Clin Med. 2025 Feb 19;14(4):1385. doi: 10.3390/jcm14041385.
10
Mesonephric-like adenocarcinoma of the endometrium: detailed molecular characterization of the first case showing a morphological continuum from mesonephric-like metaplasia and atypical mesonephric-like hyperplasia to adenocarcinoma.子宫内膜中肾样腺癌:首例病例的详细分子特征,该病例显示了从中肾样化生、非典型中肾样增生到腺癌的形态学连续变化。
Virchows Arch. 2025 Feb 14. doi: 10.1007/s00428-024-03972-9.
ProMisE 分组的临床特征可识别出子宫内膜癌患者的不同表型。
Arch Gynecol Obstet. 2021 Jun;303(6):1393-1400. doi: 10.1007/s00404-021-06028-4. Epub 2021 Mar 23.
4
HER-2 Amplification in Uterine Serous Carcinoma and Serous Endometrial Intraepithelial Carcinoma.子宫浆液性癌和浆液性子宫内膜上皮内癌中的HER-2扩增
Am J Surg Pathol. 2021 May 1;45(5):708-715. doi: 10.1097/PAS.0000000000001682.
5
Endometrial Adenocarcinomas With No Specific Molecular Profile: Morphologic Features and Molecular Alterations of "Copy-number Low" Tumors.无特定分子特征的子宫内膜腺癌:“拷贝数低”肿瘤的形态特征和分子改变。
Int J Gynecol Pathol. 2021 Nov 1;40(6):587-596. doi: 10.1097/PGP.0000000000000747.
6
Clinico-pathological significance of TCGA classification and SWI/SNF proteins expression in undifferentiated/dedifferentiated endometrial carcinoma: A possible prognostic risk stratification.TCGA 分类和 SWI/SNF 蛋白表达在未分化/去分化子宫内膜癌中的临床病理意义:一种可能的预后风险分层。
Gynecol Oncol. 2021 May;161(2):629-635. doi: 10.1016/j.ygyno.2021.02.029. Epub 2021 Mar 10.
7
DNA mismatch repair deficiency and p53 abnormality are age-related events in mixed endometrial carcinoma with a clear cell component.DNA 错配修复缺陷和 p53 异常是伴有透明细胞成分的混合性子宫内膜癌中与年龄相关的事件。
Pathol Res Pract. 2021 Apr;220:153383. doi: 10.1016/j.prp.2021.153383. Epub 2021 Feb 16.
8
ESGO/ESTRO/ESP Guidelines for the management of patients with endometrial carcinoma.欧洲妇科肿瘤学会/欧洲放射肿瘤学会/西班牙妇科肿瘤学会子宫内膜癌患者管理指南
Virchows Arch. 2021 Feb;478(2):153-190. doi: 10.1007/s00428-020-03007-z.
9
Substantial lymph-vascular space invasion (LVSI) as predictor of distant relapse and poor prognosis in low-risk early-stage endometrial cancer.大量淋巴血管空间浸润(LVSI)可预测低危早期子宫内膜癌的远处复发和不良预后。
J Gynecol Oncol. 2021 Mar;32(2):e11. doi: 10.3802/jgo.2021.32.e11. Epub 2021 Jan 11.
10
The presence of an endometrioid component does not alter the clinicopathologic profile or survival of patients with uterine serous cancer: A gynecologic oncology group (GOG/NRG) study of 934 women.存在子宫内膜样成分并不会改变子宫浆液性癌患者的临床病理特征或生存:妇科肿瘤学组(GOG/NRG)对 934 名女性的研究。
Gynecol Oncol. 2021 Mar;160(3):660-668. doi: 10.1016/j.ygyno.2020.12.040. Epub 2021 Jan 8.